This website does readability filtering of other pages. All styles, scripts, forms and ads are stripped. If you want your website excluded or have other feedback, use this form.

U.S. Pharmacopeia

Will innovations in healthcare and medicine deliver?

USP and MIT Center for Collective Intelligence report imagines health innovations and what stands in the way of success.

Read the report

Trust Accelerated:

Speeding the development of quality COVID-19 vaccines and treatments

Learn more

Previous Next

Latest COVID-19 Updates

Get complimentary six-month access to USP-NF Online

Read more

Important alcohol-based hand sanitizer information.

Learn more

A message from Ron Piervincenzi to our stakeholder community.

Learn more

Latest Standards Updates


Six New Revision Bulletins (posted 29–May–2020)

One New Publication Announcement (posted 29–May–2020)

One Updated Publication Announcement (posted 29–May–2020)

One New General Announcement (posted 29–May–2020)

One New General Chapter Prospectus (posted 29–May–2020; input deadline 28–Jun–2020)

Seven New Pending Notices of Intent to Revise (posted 29–May–2020)

Cumulative List Updated (posted 29–May–2020)

Three New Reference Change Notices (posted 22–May–2020)

One New Revision Bulletin (posted 18–May–2020)

Reference Standards

Updates on USP Reference Standards in response to COVID-19

Download full list as: EXCEL | PDF

Biologics Reference Materials

Food Ingredients Reference Materials list: EXCEL | PDF

Dietary Supplements list: PDF

New USP Reference Standards

200 years of building trust

The United States Pharmacopeia (USP) was created nearly 200 years ago, dedicated to instilling trust where it matters most: in the medicines, supplements and foods people rely on for their health. The quality standards we develop help manufacturers deliver on their promises of safe products, while building confidence among healthcare practitioners, patients and consumers.

Learn more about our legacy of trust

FDA Commissioner welcomes USP Convention Members

Commissioner Hahn reflects on the FDA’s shared history with USP to improve public health and protect patient safety, including current efforts to combat COVID-19.

USP Tweets


False Quality Matters Blog

Building a More Resilient Supply Chain Requires Transparency, Diversity, and Collaboration

USP CEO highlights COVID-19’s impact on the supply of quality medicines, and solutions for improving manufacturing diversity and data transparency to strengthen the global supply chain.

Read more

Purchase Access USP-NF